Concord Drugs Peer Comparison

BSE: 538965

₹78.33

₹2.50 (3.30%)

As on 25-Sep-2026IST

Market cap

₹103 Cr

Revenue (TTM)

₹86 Cr

P/E Ratio

50.3

P/B Ratio

2.1

Div. Yield

0 %

Edit

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	103	21,555	19,802	18,323	17,490
Revenue (₹ Cr)	86	2,287	1,682	2,570	3,230
Net Profit (₹ Cr)	2.05	678.07	273.51	735.15	666.92
Net Margin (%)	2.38	28.10	16.19	26.88	20.60
RoE (%)	4.94	19.73	11.15	19.16	18.75
Price to Earnings	50.32	32.40	66.60	24.92	27.16
Price-To-Book	2.08	5.87	7.37	4.16	4.34

Income Statement (₹ Cr)

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	86.11	2,287.33	1,682.47	2,569.77	3,229.67
Total Income	86.11	2,413.29	1,689.83	2,735.39	3,237.12
Total Expenditure	80.29	1,490.75	1,203.91	1,628.14	2,090.06
EBITDA	5.83	796.58	478.55	941.63	1,139.61
Depreciation	1.35	78.10	126.01	57.58	281.06
EBIT	4.48	718.48	352.55	884.05	858.55
Interest	1.62	0.88	52.11	7.69	190.64
Other Income	0.00	125.96	7.37	165.62	7.45
Exceptional Items	0.00	0.00	12.16	-49.16	-17.24
Profit before Tax	2.86	843.56	319.96	992.82	658.12
Provision for Tax	0.81	165.49	46.45	257.67	-8.80
Profit after Tax	2.05	678.07	273.51	735.15	666.92

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	48.51	3,586.42	2,591.20	4,202.90	3,902.67
Minority Interest	0.00	-12.71	0.00	0.00	-21.81
Non-Current Liabilities	5.31	28.74	266.35	91.50	1,392.75
Current Liabilities	21.07	385.94	848.06	627.48	2,077.10
Total Liabilities	--	3,207.85	3,310.68	4,911.11	6,865.52

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	14.87	1,291.22	2,525.44	770.28	5,617.77
Current Assets	53.31	2,585.66	1,109.77	3,803.22	1,539.85
Total Assets	--	3,207.85	3,310.68	4,911.11	6,865.52
Total Debt*	--	0.55	586.37	2.50	2,421.66
Net Current Assets	32.25	2,199.72	261.71	3,175.74	-537.25
Contingent Liabilities	--	0.64	76.22	363.79	51.96

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	--	432.37	132.27	659.75	1,065.01
Cash Flow from Investing Activities	--	-334.73	-199.13	-71.34	-79.97
Cash from Financing Activities	--	-38.32	62.65	-205.34	-881.32
Net Cash Inflow / Outflow	--	59.32	-4.21	383.07	103.72

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	--	26.22	6.95	26.21	13.59
ROE (%)	4.94	19.73	11.15	19.16	18.75
ROA (%)	2.93	18.69	7.80	14.95	9.26
EBIT Margin (%)	5.20	31.41	20.95	34.40	26.58
Net Margin (%)	2.38	28.10	16.19	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	82.54	15.01	27.91	10.69	9.59
EBIT Growth (%)	55.90	18.45	58.32	24.14	16.84
Net Profit Growth (%)	380.09	19.61	149.56	-9.09	62.68
EPS Growth (%)	317.22	17.73	-3.57	14.40	67.41
Book Value Growth (%)	--	23.77	30.63	17.30	10.19

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	43.97	32.40	70.65	23.75	26.48
Price / Book Value	2.08	5.87	7.37	4.16	4.34
Dividend Yield (%)	0.00	0.28	0.06	1.87	0.00
EV/EBITDA	20.97	25.80	42.66	16.16	17.32
Market Cap (₹ Cr)	--	15,219.80	6,484.12	18,318.10	19,292.77

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.04	0.00	0.07	0.00	0.24
Short term debt to equity ratio	--	0.00	0.13	0.00	0.14
Current Ratio	2.53	6.70	1.31	6.06	0.74
Quick Ratio	1.32	5.59	0.88	5.31	0.53
Interest Coverage	2.76	959.59	7.14	130.11	4.45

	Concord Drugs	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	28.31	36.10	30.84	7.07	21.07
Asset Turnover	1.23	0.63	0.48	0.52	0.45
Receivable days	--	110.70	118.15	29.10	54.06
Inventory Days	--	65.86	98.29	69.53	32.16
Payable days	--	105.88	128.16	76.77	140.91
Cash Conversion Cycle	--	70.68	88.28	21.86	-54.69

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.